AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18066136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (plant sterols + exercise)
Number of subjects: 84
Study 18066136 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 84
Study 18066136 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols
Number of subjects: 84
Study 18066136 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study 15766371 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal maintenance provided within the specialist clinic (Group A)
Number of subjects: 35
Study 15766371 — intervention group
Group type: COMPARATOR
Intervention: Periodontal maintenance provided by the referring general dentist (Group B)
Number of subjects: 35
Study 12412822 — intervention group
Group type: COMPARATOR
Intervention: Zolmitriptan nasal spray (2.5, 5.0, or 10 mg)
Number of subjects: 12
Study 12412822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray (10 mg)
Number of subjects: 12
Study 12412822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray (2.5 mg at pH 7.4, pH 5.0)
Number of subjects: 12
Study 12412822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (all formulations)
Number of subjects: 12
Study 12412822 — intervention group
Group type: COMPARATOR
Intervention: Zolmitriptan nasal spray vs oral formulations
Number of subjects: 12
Study 12412822 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray
Number of subjects: 12
Study 10397477 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (200 IU vitamin E, 9 mg beta-carotene, 500 mg vitamin C, 1.8 g red ginseng) for 4 weeks
Number of subjects: 5
Study 10397477 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 5
Study 10397477 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng
Number of subjects: 5
Study 10397477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 8665710 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleus-footplate assembly
Number of subjects: 34
Study 8665710 — intervention group
Group type: COMPARATOR
Intervention: Tympanic membrane to footplate assembly
Number of subjects: 34
Study 2225364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus of adenosine (16 micrograms)
Number of subjects: 58
Study 2225364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus of adenosine (12 micrograms)
Number of subjects: 58
Study 2225364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of adenosine (80 micrograms/min or more)
Number of subjects: 58
Study 2225364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of adenosine (140 micrograms/kg/min)
Number of subjects: 58
Study 2225364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary boluses and intravenous infusions of adenosine
Number of subjects: 58
Study 2225364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus of adenosine
Number of subjects: 58
Study 2225364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of adenosine (up to 240 micrograms/min)
Number of subjects: 58
Study 494988 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery (Group I, 18 patients)
Number of subjects: 70
Study 494988 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate surgery (Group II, 18 patients)
Number of subjects: 70
Study 494988 — intervention group
Group type: COMPARATOR
Intervention: Antithyroid drugs (Group III, 34 patients)
Number of subjects: 70
Study 31102008 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAC)
Number of subjects: 66
Study 31102008 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OC)
Number of subjects: 66
Study 28277801 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenAC vaccine
Number of subjects: 900
Study 28277801 — intervention group
Group type: COMPARATOR
Intervention: Licensed Hib vaccine and MenAC vaccine
Number of subjects: 900
Study 25760666 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic MTM services provided by pharmacists
Number of subjects: 4
Study 23244339 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose beverage (GI 100, GL 65)
Number of subjects: 40
Study 23244339 — intervention group
Group type: EXPERIMENTAL
Intervention: Full milk beverage (GI 27, GL 5)
Number of subjects: 40
Study 23244339 — intervention group
Group type: EXPERIMENTAL
Intervention: Half milk/glucose beverage (GI 84, GL 35)
Number of subjects: 40
Study 23244339 — intervention group
Group type: COMPARATOR
Intervention: Control group (Glucose drink)
Number of subjects: 40
Study 21314445 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidform‐diaphragm
Number of subjects: 192
Study 21314445 — intervention group
Group type: COMPARATOR
Intervention: HEC‐diaphragm
Number of subjects: 192
Study 21314445 — intervention group
Group type: COMPARATOR
Intervention: Acidform only
Number of subjects: 192
Study 21314445 — intervention group
Group type: COMPARATOR
Intervention: Control group (HEC only)
Number of subjects: 192
Study 19551682 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpupillary thermotherapy (TTT)
Number of subjects: 95
Study 19551682 — intervention group
Group type: COMPARATOR
Intervention: Iodine‐125 brachytherapy (IBT)
Number of subjects: 95
Study 17156477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide (600 mg/m2 twice weekly for 4 weeks) and gemcitabine (1000 mg/m2 for 3 weeks followed by 1 week of rest)
Number of subjects: 89
Study 17156477 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (1000 mg/m2 for 3 weeks followed by 1 week of rest)
Number of subjects: 89
Study 17156477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide and gemcitabine
Number of subjects: 89
Study 17156477 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 89
Study 12701671 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam with pre-treatment of carbamazepine
Number of subjects: 123
Study 12701671 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 123
Study 10720509 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant gp120 vaccines (various doses from SF‐2 or MN strains)
Number of subjects: 126
Study 10720509 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant only
Number of subjects: 126
Study 10720509 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated immunization schedule with lowest dose of SF‐2 vaccine
Number of subjects: 126
Study 9189105 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 108
Study 9189105 — intervention group
Group type: COMPARATOR
Intervention: Conventional appendicectomy
Number of subjects: 108
Study 8240640 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg initial injection, followed by 0.1 mg per minute until desired vigilance)
Number of subjects: 24
Study 8240640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no flumazenil used)
Number of subjects: 24
Study 3797990 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 24
Study 3797990 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 24
Study 29494171 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of research staff demographics in psychological research
Number of subjects: 0
Study 29494171 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup versus outgroup effects
Number of subjects: 0
Study 29494171 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype and implicit bias effects
Number of subjects: 0
Study 29494171 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming and social tuning effects
Number of subjects: 0
Study 27354081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin given from 11 to 13 weeks' gestation
Number of subjects: 1760
Study 27354081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1760
Study 24884424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized donor milk
Number of subjects: 363
Study 24884424 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 363
Study 22775424 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training for 10 weeks
Number of subjects: 19
Study 20045075 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6g/kg)
Number of subjects: 32
Study 20045075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18783962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 60
Study 18783962 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 60
Study 15574625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfasting ketogenic diet (NFKD)
Number of subjects: 41
Study 15574625 — intervention group
Group type: COMPARATOR
Intervention: Initial fasting ketogenic diet (IFKD)
Number of subjects: 41
Study 11376516 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 73
Study 9211212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aqueous beryllium sulfate (BeSO4)
Number of subjects: 34
Study 9211212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% petrolatum beryllium sulfate (BeSO4)
Number of subjects: 34
Study 9211212 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% beryllium sulfate (BeSO4)
Number of subjects: 34
Study 9211212 — intervention group
Group type: EXPERIMENTAL
Intervention: Beryllium patch test
Number of subjects: 34
Study 9211212 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsies at abnormal patch test sites
Number of subjects: 34
Study 8247598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (SVC, FVC, MVV)
Number of subjects: 109
Study 8247598 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's unforced adapted prediction equations
Number of subjects: 109
Study 3675502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3675502 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 mg
Number of subjects: 8
Study 3675502 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 1 mg
Number of subjects: 8
Study 3675502 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 8
Study 3675502 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 mg/d-amphetamine 10 mg
Number of subjects: 8
Study 3675502 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 1 mg/d-amphetamine 10 mg
Number of subjects: 8
Study 28983705 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly intravenous bisphosphonates (3 mg ibandronate every 3 months)
Number of subjects: 432
Study 28983705 — intervention group
Group type: COMPARATOR
Intervention: Weekly oral bisphosphonates (70 mg alendronate orally once each week for 12 months)
Number of subjects: 432
Study 28983705 — intervention group
Group type: COMPARATOR
Intervention: Weekly oral bisphosphonates (70 mg alendronate)
Number of subjects: 432
Study 27274007 — intervention group
Group type: COMPARATOR
Intervention: Glyburide alone (period 0)
Number of subjects: 0
Study 27274007 — intervention group
Group type: EXPERIMENTAL
Intervention: Piragliatin + glyburide (period 1)
Number of subjects: 0
Study 27274007 — intervention group
Group type: EXPERIMENTAL
Intervention: Piragliatin alone (period 2)
Number of subjects: 0
Study 25391692 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST scan performed by paramedics
Number of subjects: 10
Study 23782588 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg subcutaneously QW
Number of subjects: 29
Study 23782588 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg subcutaneously Q2W
Number of subjects: 29
Study 21218651 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily medication of low-dose tadalafil (5 mg/d for 6-8 weeks)
Number of subjects: 60
Study 21218651 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 60
Study 18226126 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (3000 IU/day)
Number of subjects: 42
Study 18226126 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Albumin 582 mg/day)
Number of subjects: 42
Study 16773938 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate therapy for patients with moderate or high conversion risk (e.g. elderly age, greater intraocular pressure, central corneal thickness, greater cup/disc ratio)
Number of subjects: 0
Study 16773938 — intervention group
Group type: COMPARATOR
Intervention: Thorough monitoring for patients without moderate or high conversion risk
Number of subjects: 0
Study 12729083 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch 2-step (TE2)
Number of subjects: 44
Study 12729083 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch 3-step (TE3)
Number of subjects: 44
Study 12729083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch 2-step (SE2)
Number of subjects: 44
Study 12729083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch 1-step (SE1)
Number of subjects: 44
Study 12729083 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch 3-step (TE3) and Self-etch 2-step (SE2)
Number of subjects: 44
Study 10815792 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 82
Study 10815792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 8667057 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐8 infusion (0.3 ng/kg per min for 60 min)
Number of subjects: 18
Study 8667057 — intervention group
Group type: COMPARATOR
Intervention: CCK‐8 bolus injection (0.04 microgram/kg)
Number of subjects: 18
Study 8667057 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐8 infusion
Number of subjects: 18
Study 8667057 — intervention group
Group type: COMPARATOR
Intervention: CCK‐8 bolus injection
Number of subjects: 18
Study 1601759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 0.5 g
Number of subjects: 0
Study 1601759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 1.0 g
Number of subjects: 0
Study 1601759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 2.0 g
Number of subjects: 0
Study 1601759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome 1.0 g every 12 h for 3.5 days
Number of subjects: 0
Study 1601759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome (all doses)
Number of subjects: 0
Study 3968920 — intervention group
Group type: EXPERIMENTAL
Intervention: After-hours telephone access to physicians (S1 and S2)
Number of subjects: 1849
Study 3968920 — intervention group
Group type: EXPERIMENTAL
Intervention: After-hours telephone access to physicians with computerized medical records (S2)
Number of subjects: 1849
Study 3968920 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 1849
Study 31715355 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of diclofenac diethylamine emulgels
Number of subjects: 0
Study 31715355 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of diclofenac diethylamine emulgels
Number of subjects: 0
Study 31715355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference formulations
Number of subjects: 0
Study 31715355 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheological properties of test and reference formulations
Number of subjects: 0
Study 29482717 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 120
Study 29482717 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg/day
Number of subjects: 120
Study 29482717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26695876 — intervention group
Group type: EXPERIMENTAL
Intervention: GTC‐NEX (780 mg GTC with water, no exercise)
Number of subjects: 16
Study 26695876 — intervention group
Group type: EXPERIMENTAL
Intervention: GTC‐EX (780 mg GTC with exercise)
Number of subjects: 16
Study 26695876 — intervention group
Group type: COMPARATOR
Intervention: PL‐EX (water only, with exercise)
Number of subjects: 16
Study 26695876 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including GTC‐NEX, GTC‐EX, PL‐EX)
Number of subjects: 16
Study 26695876 — intervention group
Group type: EXPERIMENTAL
Intervention: GTC‐NEX vs GTC‐EX
Number of subjects: 16
Study 26695876 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting vs Exercise-induced BAP to d‐ROMs
Number of subjects: 16
Study 26695876 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting vs Exercise-induced 8‐OHdG
Number of subjects: 16
Study 24637183 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed lateral internal sphincterotomy
Number of subjects: 136
Study 24637183 — intervention group
Group type: COMPARATOR
Intervention: Open lateral sphincterotomy
Number of subjects: 136
Study 23097636 — intervention group
Group type: EXPERIMENTAL
Intervention: Noni juice (29.5 mL to 188 mL daily)
Number of subjects: 132
Study 23097636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fruit juice)
Number of subjects: 132
Study 21179277 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-visit group (additional visit after FB)
Number of subjects: 304
Study 21179277 — intervention group
Group type: COMPARATOR
Intervention: Control group (one visit before FB)
Number of subjects: 304
Study 17958668 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-selected trained lay health workers (LHWs) on farms, mentored and managed by nurses.
Number of subjects: 0
Study 17958668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effective intervention involving peer-selected LHWs.
Number of subjects: 0
Study 15489105 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating progenitor cells (CPC)
Number of subjects: 59
Study 15489105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived progenitor cells (BMC)
Number of subjects: 59
Study 15489105 — intervention group
Group type: COMPARATOR
Intervention: CPC and BMC
Number of subjects: 59
Study 11206252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle disk training with adhesive tape
Number of subjects: 22
Study 11206252 — intervention group
Group type: COMPARATOR
Intervention: Ankle disk training without adhesive tape (Control)
Number of subjects: 22
Study 9683366 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous radiation and chemotherapy (cis-DDP, 5-fluorouracil, leucovorin)
Number of subjects: 87
Study 9683366 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 87
Study 9683366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal CT density
Number of subjects: 87
Study 9683366 — intervention group
Group type: EXPERIMENTAL
Intervention: Total tumor volume
Number of subjects: 87
Study 9683366 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 87
Study 9683366 — intervention group
Group type: EXPERIMENTAL
Intervention: MIB1-LI
Number of subjects: 87
Study 7833224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg four times over 36 h)
Number of subjects: 25
Study 7833224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7833224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 25
Study 3339500 — intervention group
Group type: EXPERIMENTAL
Intervention: CSO‐110 (formula diet composed of casein, sucrose, dextrin with maltose, and vegetable oil providing 110 kcal/kg body weight/d)
Number of subjects: 128
Study 3339500 — intervention group
Group type: EXPERIMENTAL
Intervention: CSO‐55 (providing 55 kcal/kg/d for 2 days, then CSO‐110)
Number of subjects: 128
Study 3339500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose‐electrolyte solution (GES) for 2 days, then CSO‐55 for 2 days, then CSO‐110
Number of subjects: 128
Study 3339500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GES for the first 2 days, then same diets as Group 3
Number of subjects: 128
Study 3339500 — intervention group
Group type: EXPERIMENTAL
Intervention: CSO diets during the early phase of therapy
Number of subjects: 128
Study 31941471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand desks
Number of subjects: 0
Study 31941471 — intervention group
Group type: COMPARATOR
Intervention: Regular desks (Control)
Number of subjects: 0
Study 28787250 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual visits for Parkinson's disease
Number of subjects: 149
Study 27177865 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: Radiation therapy (70 Gy), concurrent cetuximab, and concurrent pemetrexed
Number of subjects: 78
Study 27177865 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: Identical regimen as Arm A plus concurrent bevacizumab followed by bevacizumab maintenance for 24 weeks
Number of subjects: 78
Study 27177865 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 78
Study 27177865 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) assessment
Number of subjects: 78
Study 25425504 — intervention group
Group type: EXPERIMENTAL
Intervention: TIDES intervention group
Number of subjects: 200
Study 25425504 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 200
Study 24351113 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning approach
Number of subjects: 0
Study 24351113 — intervention group
Group type: COMPARATOR
Intervention: Didactic approach
Number of subjects: 0
Study 20966405 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (TM)
Number of subjects: 53
Study 20966405 — intervention group
Group type: COMPARATOR
Intervention: Supervised stretching (CONTROL)
Number of subjects: 53
Study 18238878 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10‐mg autoinjector
Number of subjects: 24
Study 18238878 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 diazepam 10‐mg autoinjectors (20 mg) administered simultaneously
Number of subjects: 24
Study 16788711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise (HG)
Number of subjects: 14
Study 16788711 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exercise (NG)
Number of subjects: 14
Study 16788711 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic group (HG) after training
Number of subjects: 14
Study 16788711 — intervention group
Group type: COMPARATOR
Intervention: Normoxic group (NG) after training
Number of subjects: 14